Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.

Abstract

The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime. (p=0026) also recorded greater relief of night time pain in the diary cards during the first seven days of treatment than those on ranitidine. Patients on lansoprazole 60 mg reported significantly better pain relief at their two week visit compared with those receiving ranitidine (p=0 007). There were no differences between treatment groups in the occurrence or pattern of adverse drug reactions during the trial. It is concluded that for patients with duodenal ulcer, lansoprazole 30 mg or 60 mg is associated with faster ulcer healing and better symptom relief than ranitidine 300 mg at bedtime. There were no significant differences between lansoprazole 30 mg and 60 mg. These data indicate that lansoprazole should be used at a once daily dose of 30 mg for the treatment of duodenal ulcer.

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status*

“…17-1g Lansoprazole, a benzimidazole derivative, is a proton pump inhibitor that acts on the membrane Hf/ K+-adenosine triphosphatase in gastric parietal cells?0,21 This drug is being increasingly used in the treatment of duodenal ulcer, Zollinger-Ellison syndrome, and other related hyperacidic conditions. [22][23][24] In humans, lansoprazole is extensively biotransformed, mainly by hepatic oxidative metabolism.22724 Human clinical pharmacology studies have shown pronounced interindividual variability in plasma concentrations of patients receiving the same dose of lansoprazole. 24,25 Previous in vitro human liver microsome studies18,19 on the metabolism of omeprazole, a proton pump inhibitor structurally similar to lansoprazole,26 have shown that the production of the hydroxylated metabolite is mediated through CYP2C19.…”

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid‐related dyspepsia in general practice

“…8,9 However, no comparison has been made in the relief of dyspeptic symptoms in unselected patients presenting in general practice with undiagnosed acid-related dyspepsia.…”

“…In the treatment of peptic ulcer disease and gastrooesophageal re¯ux disease (GERD), the proton pump inhibitor lansoprazole has been shown to be superior to ranitidine and the other H 2 -receptor antagonists in the relief of symptoms. 8,9 However, no comparison has been made in the relief of dyspeptic symptoms in unselected patients presenting in general practice with undiagnosed acid-related dyspepsia.…”

A prospective follow‐up study of 5669 users of lansoprazole in daily practice

“…Lansoprazole is a new proton pump inhibitor which produces a prolonged decrease in gastric acidity. 1,2 The drug was introduced onto the Dutch market at the end of 1993 as a 30 mg capsule indicated for the treatment of re¯ux oesophagitis and the healing of gastric and duodenal ulcers. At the time of introduction, lansoprazole had been evaluated in several thousands of patients enrolled in clinical trials.…”